ERBB2 and neoplasm: Antigen-specific IgE antibodies against targets like folate receptor alpha (FRα) and HER2/neu have shown enhanced anticancer efficacy by engaging FcεR-expressing effector cells in the tumor microenvironment (322–324, 348, 349).